jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Dec. 02, 2024

April. 08, 2026

jRCT1031240517

Impact of BioFire FilmArray Pneumonia Panel and Gram stain for ventilator-associated pneumonia on antimicrobial stewardship and patient outcomes in Japan: A multicenter randomized controlled open-label noninferiority trial (FASTVAP trial) (FASTVAP trial)

Utility of BioFire Pneumonia Panel and Gram stain for ventilator-associated pneumonia in Japan (FASTVAP trial)

Fujitani Shigeki

St. Marianna University School of Medicine

2-16-1 Sugao Miyamae-ku Kawasaki-city, Kanagawa

+81-44-977-8111

shigekifujitani@marianna-u.ac.jp

Hosoyama Akiko

St. Marianna University School of Medicine

2-16-1 Sugao Miyamae-ku Kawasaki-city, Kanagawa

+81-44-977-8111

kyukyuigaku-001@marianna-u.ac.jp

Recruiting

Dec. 02, 2024

Jan. 23, 2025
175

Interventional

randomized controlled trial

open(masking not used)

no treatment control/standard of care control

parallel assignment

treatment purpose

18 years of age or older who have been on invasive mechanical ventilation for at least 48 hours and are considered to have newly developed VAP, and who are admitted to the ICU or a general ward in which a patientis under care of an Intensive Care Specialist, or who are going to be admitted due to the newly developed VAP.

Patients who were started on a new antimicrobial agent between "72 hours prior" to the collection of the endotracheal suctioning sputum or BAL specimen for the suspected VAP condition under this study and the collection of the specimen (continuation of antimicrobials started more than 72 hours prior to specimen collection is not included in exclusion criteria).

18age old over
No limit

Both

Ventilator Associated Pneumonia (VAP)

In the intervention group, antimicrobials are administered based on the protocol that decide the antimicrobials from the Gram stain and the BioFire Pneumonia Panel test result of respiratory secretion specimens.

Ventilator Associated Pneumonia

FilmArray, BioFire, Gram stain, Multiplex PCR

D053717

D060885

Clinical cure of pneumonia at 14 days post-randomisation

Proportion of participants on antibiotics active against the causative pathogens at 24 and 72 hours post-randomisation
Proportion of participants on broad-spectrum antibiotics at 24 and 72 hours post-randomisation
ICU length of stay
Number of ventilator-free days within 28 days post-randomisation
Mortality calculated as deaths from any cause within 28 days post-randomisation or hospital discharge
Mortality at the discharge from ICU
Incidence of new infections within 28 days post-randomisation
Insidence of specific adverse events associated with antibiotics within 28 days post-randomisation
Days of therapy (DOT) at 14 days and 28 days post-randomisation
Days of antibiotic spectrum coverage (DASC) at 14 days and 28 days post-randomisation
Number of antibiotics-free days within 28 days post-randomisation
Detection of new multidrug-resistant organisms
Hospital length of stay

Japan society for the promotion of science
St. Marianna University Medical Ethics Committee, Clinical Research Section at St. Marianna University
2-16-1 Sugao Miyamae-ku Kawasaki-city, Kanagawa, Kanagawa

+81-44-977-8111

k-sienbu.mail@marianna-u.ac.jp
Approval

June. 06, 2024

No

none

History of Changes

No Publication date
3 April. 08, 2026 (this page) Changes
2 Aug. 15, 2025 Detail Changes
1 Dec. 02, 2024 Detail